Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR) have been assigned an average recommendation of “Buy” from the eight brokerages that are covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $34.88.

A number of research analysts recently issued reports on XNCR shares. Wedbush reissued an “outperform” rating and set a $38.00 price target on shares of Xencor in a research report on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $20.00 to $30.00 in a report on Monday, December 2nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $34.00 target price (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Finally, Wells Fargo & Company began coverage on shares of Xencor in a report on Thursday, December 12th. They issued an “overweight” rating and a $37.00 target price for the company.

Xencor Trading Down 1.2 %

Shares of NASDAQ XNCR opened at $18.28 on Monday. Xencor has a 1 year low of $15.31 and a 1 year high of $27.24. The stock has a market cap of $1.28 billion, a P/E ratio of -5.71 and a beta of 0.72. The firm has a 50-day moving average of $23.05 and a 200 day moving average of $21.06. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $14.59 million. During the same period last year, the company posted ($0.40) EPS. Xencor’s revenue was down 81.9% on a year-over-year basis. As a group, sell-side analysts expect that Xencor will post -3.68 EPS for the current fiscal year.

Insider Activity

In related news, Director Alan Bruce Montgomery sold 1,421 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $27.03, for a total transaction of $38,409.63. Following the completion of the sale, the director now directly owns 9,140 shares in the company, valued at approximately $247,054.20. The trade was a 13.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP John R. Desjarlais sold 68,684 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the sale, the vice president now owns 200,104 shares of the company’s stock, valued at $4,698,441.92. This trade represents a 25.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 136,050 shares of company stock valued at $3,277,609 over the last three months. Insiders own 5.23% of the company’s stock.

Institutional Trading of Xencor

Several large investors have recently added to or reduced their stakes in XNCR. Sanctuary Advisors LLC bought a new position in shares of Xencor in the third quarter worth approximately $540,000. Barclays PLC boosted its position in shares of Xencor by 100.7% in the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock worth $3,128,000 after purchasing an additional 78,066 shares during the period. AQR Capital Management LLC bought a new position in shares of Xencor in the second quarter worth approximately $753,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Xencor in the third quarter worth approximately $362,000. Finally, Jane Street Group LLC boosted its position in shares of Xencor by 18.6% in the third quarter. Jane Street Group LLC now owns 168,431 shares of the biopharmaceutical company’s stock worth $3,387,000 after purchasing an additional 26,473 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.